Shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) saw unusually-strong trading volume on Tuesday . Approximately 1,678,035 shares changed hands during trading, an increase of 656% from the previous session’s volume of 221,908 shares.The stock last traded at $1.19 and had previously closed at $1.02.

A number of equities research analysts recently commented on EYEG shares. Noble Financial restated a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Friday, May 19th. HC Wainwright set a $6.00 price target on Eyegate Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd.

The company has a 50 day moving average price of $1.14 and a 200-day moving average price of $1.79. The firm’s market cap is $20.47 million.

A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. raised its position in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the period. Vanguard Group Inc. owned approximately 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent reporting period. 12.99% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Eyegate Pharmaceuticals, Inc. (EYEG) Sees Unusually-High Trading Volume” was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.